A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials
- 16 January 2004
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 303 (5656) , 316
- https://doi.org/10.1126/science.1094620
Abstract
Concerns are expressed by a group of AIDS researchers about the U.S. government9s plans to conduct a phase III trial of a combination HIV-1 vaccine in Thailand despite the cancellation of a trial of a very similar combination vaccine in the U.S.A. last year. One of the vaccine components, recombinant monomeric gp120, has already been shown to be ineffective in phase III trials in Thailand and the United States; the other component, a recombinant canarypox vector, is also poorly immunogenic. The scientific rationale that has been offered for the new trial in Thailand is considered by the authors to be weak.Keywords
This publication has 8 references indexed in Scilit:
- AIDS Vaccine Still Alive as Booster After Second Failure in ThailandScience, 2003
- AIDS Vaccine Trial Produces Disappointment and ConfusionScience, 2003
- Comparison Between Env-Specific T-Cell Epitopic Responses in HIV-1-Uninfected Adults Immunized with Combination of ALVAC-HIV(vCP205) Plus or Minus rgp160MN/LAI-2 and HIV-1-Infected AdultsJAIDS Journal of Acquired Immune Deficiency Syndromes, 2003
- Disappointing Data Scuttle Plans for Large-Scale AIDS Vaccine TrialScience, 2002
- Cytokine responses to human immunodeficiency virus type 1 (HIV-1) induced by immunization with live recombinant canarypox virus vaccine expressing HIV-1 genes boosted by HIV-1SF-2 recombinant GP120Vaccine, 2001
- Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing HIV‐1Mngp120, HIV‐1SF2Recombinant gp120, or Both Vaccines in Seronegative AdultsThe Journal of Infectious Diseases, 1998
- Immunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp120 Subunit VaccinesJournal of Virology, 1998